-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Ez+ONs3J/MxfLK+Mr8la3vZdR28iklOevgJitUP4eeL7dre3TzUlVSNTbOFPfm7m vLEHGG5zdWi9h46mc6FQ0w== 0001193125-07-092094.txt : 20070427 0001193125-07-092094.hdr.sgml : 20070427 20070426192544 ACCESSION NUMBER: 0001193125-07-092094 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20070424 ITEM INFORMATION: Termination of a Material Definitive Agreement ITEM INFORMATION: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20070427 DATE AS OF CHANGE: 20070426 FILER: COMPANY DATA: COMPANY CONFORMED NAME: US Oncology Holdings, Inc. CENTRAL INDEX KEY: 0001333191 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOSPITALS [8060] IRS NUMBER: 200873619 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-126922 FILM NUMBER: 07792861 BUSINESS ADDRESS: STREET 1: 16825 NORTHCHASE DRIVE, SUITE 1300 CITY: HOUSTON STATE: TX ZIP: 77060 BUSINESS PHONE: (832) 601-8766 MAIL ADDRESS: STREET 1: 16825 NORTHCHASE DRIVE, SUITE 1300 CITY: HOUSTON STATE: TX ZIP: 77060 FILER: COMPANY DATA: COMPANY CONFORMED NAME: US ONCOLOGY INC CENTRAL INDEX KEY: 0000943061 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-SPECIALTY OUTPATIENT FACILITIES, NEC [8093] IRS NUMBER: 841213501 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-26190 FILM NUMBER: 07792862 BUSINESS ADDRESS: STREET 1: 16825 NORTHCHASE DR STREET 2: STE 1300 CITY: HOUSTON STATE: TX ZIP: 77060 BUSINESS PHONE: 2818732674 FORMER COMPANY: FORMER CONFORMED NAME: AMERICAN ONCOLOGY RESOURCES INC /DE/ DATE OF NAME CHANGE: 19950327 8-K 1 d8k.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of report (date of earliest event reported) – April 24, 2007

 

US Oncology Holdings, Inc.

US Oncology, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware   333-126922   20-0873619
Delaware   0-26190   84-1213501

(State or other jurisdiction

of incorporation)

   (Commission File Number)  

(IRS Employer

Identification Number)

16825 Northchase Drive, Suite 1300

Houston, Texas 77060

(Address of principal executive offices including zip code)

(832) 601-8766

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrants under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

ITEM 1.02. Termination of a Material Definitive Agreement.

In connection with the retirement of Mr. Morgan described in this report, Mr. Morgan’s employment agreement with US Oncology Holdings, Inc. will terminate, effective June 30, 2007.

 

ITEM 5.02. Departure of Directors or Principal Officers

(b) George D. Morgan, Executive Vice President and Chief Operating Officer of each of US Oncology and US Oncology Holdings, Inc., has notified the registrant that he will be retiring, effective June 30, 2007.

After Mr. Morgan’s departure, Bruce Broussard, President, will oversee the registrant’s operations team, and Atul Dhir M.B.B.S, D.Phil, will be appointed Executive Vice President, Pharmaceutical Services Group and in such capacity will assume responsibility for the registrant’s pharmaceutical distribution, specialty pharmacy and pharmaceutical manufacturer services operations, as well as its Oncology Pharmaceutical Service Line business. Dr. Dhir will report to Mr. Broussard.

 

ITEM 9.01 Financial Statements and Exhibits.

The following exhibit is furnished as part of this Current Report on Form 8-K:

 

(c) Exhibits.

Exhibit 99.1 Press Release of US Oncology Holdings, Inc. dated April 26, 2007.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 25, 2007

 

US ONCOLOGY HOLDINGS, INC.
US ONCOLOGY, INC.
By:  

/s/ Phillip H. Watts

Name:   Phillip H. Watts
Title:   Vice President - General Counsel
 EX-99.1 2 dex991.htm PRESS RELEASE Press Release

Exhibit 99.1

LOGO

 

  Contact:   Kimberly Rutherford
    (832) 601-6193
    Kimberly.Rutherford@usoncology.com

US Oncology’s Chief Operating Officer George Morgan Retires

(Houston, April 26, 2007) US Oncology announced today that its chief operating officer, George Morgan, will retire effective June 30, 2007. Morgan joined US Oncology in 2000.

“I have enjoyed my work with US Oncology and am proud of the great progress and growth we have accomplished. While I will miss working with the many talented and committed people within the company, I am looking forward to this next stage of my life and to spending more time with my family,” said Morgan.

“It has been a privilege to work with George for the past seven years. His tremendous depth of knowledge and his significant contributions to our business has helped US Oncology achieve operating efficiency levels that lead the industry,” said R. Dale Ross, Chairman and CEO of US Oncology. “I wish George and his family the very best. We will miss him.”

Bruce Broussard, the president of US Oncology, will now assume responsibility for operations.

About US Oncology, Inc.

US Oncology, headquartered in Houston, is one of the nation’s largest cancer treatment and research networks. US Oncology provides extensive services and support to its affiliated cancer care sites nationwide to help them expand their offering of the most advanced treatments and technologies, build integrated community-based cancer care centers, improve their therapeutic drug management programs, and participate in many of the new cancer-related clinical research studies. US Oncology also provides a broad range of services to pharmaceutical manufacturers, including product distribution and informational services such as data reporting and analysis.

According to the company’s last quarterly earnings report, US Oncology is affiliated with 1,067 physicians operating in 425 locations, including 91 radiation oncology facilities in 37 states.

# # #

GRAPHIC 3 g15348logo.jpg GRAPHIC begin 644 g15348logo.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`F`"/`P$1``(1`0,1`?_$`+,```$#!0$!`0`````` M```````("0H"`P4&!P0!"P$!``$$`P$```````````````D#!0<(`0(&!!`` M``8!`P,#`@0$!`,)`````0(#!`4&!P`1""$2"3$3%"(505%A"G&!(Q8R0B07 MD:$FX5)BS[7.':A5&]ON_M:4NH**4*&;*@0I M6D]TD`$XE)[&(T_O(YQ!JF..MJN)<12O!VJ4,O>0I.E(/@H*!E/'K@(=K\:? M+(G*_CC"S\T!4,A4%5#'^0VZK\CYR^FHYDU.RLZIB@18&]HCQ*X*)RALM[I? MPUKAS5QN>/=]5%"@?_SJD^\V0)`!4II'3R3D/"6$;6_;IRHCEGCIBZ`C^OT0 M#+J9R)TY&1/49^,.*IF`P"("`[#MT'TZ`.WZ#L.L3$I5)2X'G+TF9B\R#.E<5C%]>=&`QY6 MUNT3&3?KM@,592#KZ`"\=G*(`!4P)N!CEWR7Q!L*JY'WJS9@E0LS:@I]P`JP M$U:`!*15*6J>&.&$86YUY28XLV+4W-!2NZ/HT,MZPA0*O*7)R)\H)PECWQB" M?+3#^PR\M/3KA64F9N1?S$J_=F]Y9Y*2CQ=\_=G,?N,)G3E?*N=*VE.X:%6I)"=:EI$YIF)*$P>Q MR&';8;[6N3*SCWD1A@N*38*\E#J2O2D$Y*Q$B9I&!EBTQ#%$ MQ#%4[@.`B(E,0>O<0P=0'?80'IJ*/V?:"@GU`G#MX?X$3:!VG7I4EP*#DB", MC/KGUBZ!Q[NT0V`0#8=_7IU#;;\!UU"D^VE1]1,I>,4O=(J%,*$@!@>^47-< MQ6@TA!I"#2$&D(-(0:0@TA!I"#2$&D(!]!_AI.6/:.""00,Y1H62LB4_%5)G ML@7VP1M9J589&D)N:E72+-JU;$$"@4%7!BE.YU9+,A:ZZI6``D$DSS&1EG,G(`8Q8K_N6V[3L[U]O+B6[?3H)65$"9`GA M,B9P,@,X@LJ;C]8@0NQ2@&I?>'.,+/Q;M5NGT)7>G4!;KDL2LX2GV$L!TB#OG;EZ\ M\J;K=JU+4FRMJT,(R`;!)_$G&$:AN4.[\QW_`)`.LKN*"J1MW^);@'PF8PRM M'NK]HGTH_;*/I=C'V./0X@!MC=@@4.HG`_\`[79L`]WJ4=A#J`:IU%,TV2EX M:J=Q.G3GB?A'TJ#U,I(IE2>9`6"#UPR\1.)G/B1YG!R3P0VQYXXW>;E1IG9 MJ]*74$>E*E*.I!Z##S#XRZ1,K]J/+])R/L9FSW!6K<-"2VH$^92$)3I5XXS& M60AW`!$PE]!`.NX^NVM?_P`K2%',Y?&-J4!*@=8_,23C%S7$6:6[7JGXUM2]5!2S75$ M&@&`"B&X;`8QM@[A,`")@#KL/7;IOZ:W>6,9C(XQ'@\ M0I>I$PV?3/ME^,&NL48-(0I[A]R/G>*6?:)F6),\<1,*_&,O,(V<&3+8*1,B M5I.1JB>_8LJD0Q7;U+N*WD>U[J4O`SD6E'2JKCF_57*%*J60:1+- MYZJ7&!8S\%+-1`R3J.D42K(F'T%-5/J14@@!B*%$H@`AJ'NY6JHL%R?V]<$* M;KJ9Q04DCJDR,OJ)>&,3N;>OU'N:TTU\M;B7+;54Z7`00?,H#L<"/,#XB-[U M\<7J#2$&D(-(0:0@TA!I"#2$&D(-(1\$0#;\Q]-,!B-6#[WEJR.V+(E?AU4X5-^LV+M>KWINNEVW1I4I3KR-93_``M:A[B\<)I3,]<98&,>\E[YI=@;%J]T MUI0'6V5^TA1("G=,FTX8R*B)RZ3B`QD[($YE.]V_(=D='/%6K5H"@$31$YQ2*`!OJ9.PV*CVY9Z6Q6\D45*VE&0'N:0! MJ4!@"93,NI,0*;GOE;NJ_P!7N.XR365CJEJ`,PG4HJ*0H^8I$Y"?01H?T=OJ M85.[KZ=O9L'7?UWW_EJ[..J!#:)%WY-6/JE!JO'/M#O%13B00,4"]R9RJ%,)0$Q3=IB M[E$?3G;A[B-U(+B="O7`$U'4I46RZQP!NRLJ7HZ`1Z-$*U)G'`GU@UVCF#2$&D(-(0:0@TA!I"#08Y0 MD8\CERBW+[BSA)NB0IS*JJJE3(F0H`(F.8XE3(7?IN80VWURAM?NA8"E"6G2 M`2229C`8Y3BG4I":LR9>$1%/,CS17S5DQC@N@3BJF-<<*K MGL:$?)QS^$NEK.H55G+$?PLS*1X1-PW<>X!BE'4D/VP\7#:=M7 MNV]TZD7RJ!#:7$%*T-E('I6D*23-6KH9#M$3'W?\R?WQN-.R[)4MG;U()K6V ML*;6XDD^I)TD^5(`\>LX9(W_`.'KML&P;^NP>A=_QVUMO&D.L'$F*=PZ@/;Z M`([B`"`;[;^NOGJ'/;2`TDJJ29"0),N^'3.'D41J)EX1WW!?&?,7(]>]-\3U M5S/FQU1Y:\6-8PE;MDF,8519");N#I'1<6*;(54&+;0Z2XUVWZ=UV@ME M*X\HH0I4RVA2P@2S6=,@G$DY`QP7?N#8`-W`!0[>SL]"%[Q,02BJ53N$`,`C ML4Y3!KV33B'D!QE06V1,$&8([S'3QC'S[:J=Q3+XT.I40H'`@CH0H;"`_GU#^.BG0AA2F3-:QIPQ_#XQ3>>"J=#*!YTK)G\9?NC*U]_,QLY#25< MD%(R=C9>-?0LBBY*S/'R[5\BM&O"NCK()M3(/B$,*ACE*381$=@'7RO6AFNM MJ[=>2AVVO)(<3@KRG,2Q^DHN-FN%3:+M3W2VE:;LRXE393.84/ACEXQ/,X+< MGX?E;Q]JN0TG+5.WQ:?]I90ADW*"[B$R!!ID;3B1P;G42,S?J`#EJH0QTE$E M?I$=AVAQY3V'6<=[UJ+.Z%JMBR76%R\KB#/%$L"`1+#M$[O#/(U%R;L&GO#3 MB!=$)#3Z9C4A8`,E#-)(4#(]3"RB_P"$.N^_4!_/?6/&?1/NHGZF<99EIDDY M@`?015JK"#2$&D(-(0:0@TA!I"*!.':(]?0OIU_Q#M_RWUT1Y$)5W/XQV0=6 MA7>&>?*/S[J7'.DO<55N/AK?E^UF8))5N8!H_A8B"%5L[>S-@8I2C24*5=I[ MA&1DR"`.TP[]BAN.R'`W#]UY`W`U=0X6[-3*!61@K5/`#`C(=ZE,D92")8DX]Y1#<,)A,8P@0IS&.;'9Z^^7!FVV]M3E0^X&P$Y^:4S](G.\XANH. MHAN6^2:OE#>;MX=$K4TXI+")Y`*P5X*5($]L!TBW<1;)I[5*=PJ64N MU1[JT@J1\`5*$1B?*UQ(=<9^1WT_\` MIAVI_;Y%S\MN`[=S5STZ)FVWT^V[E!O?&QD[>J5RW%2*]LDD:EMC)?>1G++, M'&(T?NUXB''/(BKG;FRK;UT'O)(GI0LC%,\I^4GX$0UZ)1*(@/00$0]0'J`[ M"`"`B`@!@$-PZ#^'36QC&E*5-)$M"BGXD=8U5PD`.@D?C&1B7;%B^2>O6AW1 M6R9E46Y#-115DDP(9D=V1T@JDI'_`""@"J(`'>4=Q-JJI(6-*SI04CJ5AOD"V;0Q&D0[R6I(KL<)Y"9Q MD$D@RIOSJLN=A-N7B1".!:$4[C&W-K0SGGCNLNKALS"U/WMW764"@J:DTJ?, M\R5+SD4+*4#(+2,`(D/^W3DBFL%(U?7&O8MZG$TES;`P0ZH@-U`&0!6X@%6' MH/7")1#-1)9J@L@H19!9,BR"J1P42515*"B2B2@"('24(8#%$.@E$!UHW)T$ MH?3H=2HI(R])E_Z1):VZP^RV]3*"Z9;:2E0,PI)2"%3ZS&,X].D=H-(0:0@T MA!I"#2$?!]!_@.D,.N4LXKJZ]IMK_X,61TPCTE"-UW1UGK\XD:IE2; M@90R91`5%3="D2(8PB`!OJY6.T5>Y*U-HMZ2:I)Q&67CXQY_<6XZ':UH%TKE M#],E1"3W&$IQ"0YN<@(;DYE2\9`MJS2&GX2/&O8ZC:-"JJUJTQI;I*'&>M$W M,R83D(MDW38=CI6;:%ENK`6^75":2E.E(; M"0`03@03AB03E$+_`#EOFDY"W=4W.Y%L/4ZUH:#0(3IU8:IE1)T@&8P\(068 M=Q$PB`]VP[AZ#N`#ZB`;[;^NM@W5%UH%PZ5C/3A/XYQKC+4YI0)C(3Z145,Q MA*!0$PF`=B!L!QWZ`!-^AC;B'Y=-]=U-.)2D@:BKM'5(3J4'#)*>L/\`OA!X MA.+??'G*NZQ)@J=&^1#XP1>(G]N;N;A`[>8LK,3"!56M;8+&02-V]7#DVP[I MZT<^[;D]NEMK6QK(ZDU#Z0M^6)"=13H)!P)D#E.4\8D)^R;A^JN-\_XSW[<>/MX4M]MO_94=+B2" M0I)P((!$R):A_P!0[&,7\N\:V[DK8E18+DDJJTI*VEB06E0F9`D'`@D991`G MLU;F:;8IRHV)@>-L59E7T).QYQ[@;2K!RHB[(D<-@4;&.'ZFS71.E^G=4C#J`2`3GC&"]=RB M(@`@8H]NX&V$H@.VW4!V'5Q0$I5)T!4LQT,6M!:2H.&91.$AAAC*MX M1WN[)XV8XCRY'J0.0\=JDA8N,.W.NV6QLHQ:/L:@G:6X?8[3--Z:L@G(.6I@ M`7*"@F3*/K'7R7:J9-Z5?[&L.V:J,UG(BIG*H&G`I0'=6@$>DC$XF)1N'MT5 M;UCIMJWY`I[_`$[84AN14/T:@#2'W$DH4X6-&N1]4_*,@N(#F[BE'\?40*.P MCUZ!UZ;:QNGRC0ZH%W/##",V`J4LD)_)E@9B<_AG%W7,=H-(0:0@TA%(F*7; M<0#?TW_'^&F9EUCL$J5,@8"*%5D44U55E4TDDB&.JHJ\G//*S9%R]D3"F%\@1\)BO M'M&?UN^3IW[<&-AN3>5C9Q9*G.V2BKIV_`&*$.(D*HBDW,1'@M(F9M6\H0XN#)D0`YRAW@([:W#N=]ME@]NAKZAAIU2`6T*(20 M#@!C(3*C(#.<:2T6WKUN#W+A0TM0[3-R]UP))2%2F<>F1G&K2[:.:3#]K$NG MTA%MWBB+)W)1_P!I?N$$S=O>ZC??B0&+!LX!62[_]8B*J3M4#'*<0U$1NJLN% MSOE3=KRM:KB^\7"E7J0#Z4R\!D.B2(G.XYMULM&V:>U6,(1;*9'MZD@`.*&* MEB6>)TDYS3+I'?C`/:3H;7;B=(XFRP;)$+&+N:_86/WB6FRL6[%!\123;M#" M8&9?C@[@7,BW9+&-VF,@X14[0(EJ3?[8^3F[Y:!9*IU`JZV_N%V_L-K51OMAPN@>4**E:A\1A/XB&7>P2B8Q_P#$`")1 M$``#FWWW`/38?4-;4LK]^I4\<60<^A^<:0I4V2A!DIH'S"?3XP`(&,(*"4P' M$I3":?*G$A)"4I.*M0EACTSCZ6'T MM*0^D#W=8(FM7ETD'&)+'![EH?*%#R]E&";H1F?^/V.$9MK1$6C9*C6/%=>: MQ?W=O'K.G1%F\PX@ZX#(B[D048GZIB*:Y@&.[EWC?^W;_1V1D+5MJ[56+AU% M3%4^K6E"Y=5J6HI2/4$*)RB2S@OEM_<.WJ_==<\$;FL=O3)D!)]^CI$>VI:5 M&1*6TI;"S+RE8`G.)"V/+O$9*I=,R#``[+"7>LPMLB$GR1VKU*,GHU&29E>, MU0!5!R"+DH'*;T,&M0+I0.VNY.6YV2GV'E(41C@)X_6-_;%=F=PVJFOK"`EA M]L*$U&84T;YKYXO4&D(-(0:0BTH7<2".VQ1[M]]AW#;8`W';8?QU MQ-T*TH]!203V/0_C%)U@.@+`)6A0(`Z]Q\X;K\EO("G87XTWV%F;P\J5QR;% M.J;0T8-%9[9)*6=ME':[5DW8&,]8-Y2/8KLP?G`J+=18-S@82@.8>#-DWG=& M_:1ZCID55#1'6\',$J$\""9`J25!02#/RSRC`GW);]M6R^.*QA5?^EO-:D): M*<5(D03@`9!24%))P\T0SJ[#3>9<@ITLCXT"$M(6R>;QK]28GB0[^.B)"6EV MQ6B1'0_?&\_[TY,P[1388IC6"QVYFX1!QD6 MWUMHU-DVVM+.#.PI5V7N_M#+0<&E'*M4%HIBH@F!DQ$XB<1V\XK9ENW5>1NV M^*6XHD&G0HGVT`8*4$2EKU9*(F/X91Z/^_[MM.S*VS:D(8!F'E]729D*!GD` M92^L)W3(_G)-%%`JKN3D5O:(JNJ05%W!4A$3JJJG(4#E(F)MS&W$I=Q'<=9# M#ZK4U[(TBER43T3_`!'Y"9^48Q90[7OD/.3<69RD223T'Q,A\3$M#Q5<&$J' MQ];W#(\<_93V:6T);YANVF2BF[JB:3Y>G5ITFW$'#1NB@]2E%")>V!G8E`_< M!-M1H_<=RW3WS>)I;3^906]2F$F4Y+&E*EC"6(01/*1PB7#[5>&WMN;'3=+R MV6:FN*70H8+4T2I24JS(P4F8(!PRA[F,9(QS)NQ;))(-&B:;=HBB0$TD6R)" MIHI)IE*4$R)$*!0*````'36L2UN.**W3J63.?>>,;H4Z64-Z*9`;IDX)`PP' M67QG&0UUBO!I"$[\G\(QV?\`$-RQZY28_JV=NRX[.W!2W2B64M>Z`Y*?HU">`\)_A&.>4=A MV_D39]98:A/^\+*BVK#U:3I&/B`(@)9)H4YB^]VG'EC201GJ=,OH*6;MG;1Z MDW=,5UD#(@NT652.8J:/<;8?I#IZ]`F,VK>[?N/;])<+>XE:5-)4J1ZD1`WN MG;E?M.^UMANK2FJEEY8&H$$@'`]I$$2QC1M>CCRT=8P_E"9Q9:`EF4C.)5R; M:C5M>Y9)C(L^[ZB!W)J@4P#ZZ\IN_;#&Z[,[1N M-(-2V1["R`2FJ4%>RX)]6_-++//&/8[(W76[3OS5:RXL4*P45"`9!RF44EUL M^"P`#$L#QPY=M;RS0-8<.K).XAS!AF"R#BV4GIAK85*U=,<(QU#R11ON#.1E M`8)*QJ49))-G)T%$C**;%W.;:-/FK;UHMBE(9*47^@N"J=]*4E(=;<;#S;QF M,YK*"4D@J2>T2W_;WNF]7"J;=4HN;:O5O_5LB<_8<;<4PIK`X32SJD0#YAWA MY4!W_#;]!$.[;\Q`!$`WV_/6OL;9Q]TA!I"#2$>)ZL1!,553E302355754,1 M-%%$A-U%5U5!*1)%,NYC&$0V`-_3?7533KP]II2DJ40,$ZB9X2S_``QC@ZDC MWP4A*!,S5I'?'/*41&>?V18K,&4>0DG+L\*R5:A6F/Y-*TQF3QMM[4C06DJY M6T\/K.8UHRBE&+M@X&:8-2K(F4Y[W([NJ]7IQ9HA0H*4^9[W2"D-C\L*1Y#ACI\>YAG M-C+DWQ'*AQ,U3Z` M`EZ:VDJ;6R4:5%Q31*3I*II&GH`5FV#Z'5>GC[$NHRDV\FI&UMTJM$^ZP7.Q5;2MD13 M39KII"L*8F`X[]-!/>7RA1?CEB\#SG*;'##D1(LXJEEDD9>'^['%K#OKA#.224"PFI) MTX:,XJOJN$BJN3..\B_:FB``)C:QSSM4[P8X]>K=G-K%Q4A27"!K4&B`%Z$R M/FTE4B)$3F#A&5/MTIM@7+DQBEW[[2K6A0+6(;`<3J*"M0(FG6$ZDG,`@X&) MN33*F(_912C,D8Y,W*1-!!)GOLZ>.SJF,&Q$4U#[ MF+N&PZNUIV+O&M"6:.W53J,0#H7.8Q(F1TGU(\(L-ZY5XZLA"Z^\TB$F6`4C MK,#^+N,9#".<#S_XB'9-GS//N.9$KM-%PFU0L48C((LS["=VX82#B.DN>TUV.27)$@)9-\R/*2[$)2/8N-DU%F MX&`3#]("`".J+G&^_FDZW;54!,A/RK,IY`@(.)BL.:N,B2!=J8R/\Z,?JH1; MD>9G%V.KD]<7F>,:HUNN'32E9!*T1ZYRJ'3,HD5FT;K*NI'Y(%-[(MR*"<2' MVW[1T:XXWZ[5IMHM57^K<22$Z%'#O.0`EX^$=JCF3B]-(*XWND2EMS$:T3.7 M34"0<8B_^7[,G%;/&1,9Y!X[W",M5G^S34#D9Q"1CB-C#M&JS=_`/7AW,8R7 M>S"RKU<@GW,`DV[AZ!K?+[8MN[YVU;JJW;HI'VJ(*"FM95-.$E"6(T=A,8DF M41J_=_NCC'>E[I[QLVH0[=$IDZ4:=*L.P,IX"9E/#QAG;6V4:41<*93L$"F' M8A^\`W]-RB4?Y;?AKAIQ25K+I/MMJ0XCIYT@R)[XG(Q794E+J/<`*"2/CB)S M[P\KXL>4:M/5PK")N&\0T=W6=()IR.1LSV+?(0SJ2^(D MNU;.0(W>.E#$[3&,`:U$^Y7C9FMIFMR6VE)==2E-2M.>A*E*2LIR)!DDK'F" M#+$"-Y/M3Y6J['6+VU<7T$)4?TJ%R"4J5I"DA6)"2G4=.(*L*$J(2N?MS'0$XXG'I$K='4J>:2MW2"A`+DC/&67261C8"#N4!W`=_Q`-@'K M^6J:>52Q%C_`"'@FJV55KE>>F6>,:@_<]SG;=D6:JVG:*IA>XUTZP\T0YJ0%I_*(6)(FKS3DHD2QE.(D M93(V!)E',821D;8YEW)FZ[!=04E8YWV+L82*@DTS$2%N^4<*B`#N4%-@#8-2 M7M,_T9X%Y2D4K:0E&H)Q_9A\P(B-**JY-$4QU5SZU+<223WGC/'`#'&<7JA0 M;M?G[^.IMQT[P2V[Q[M]7&VH)7[A6$MJ&TQ@9=\ M08Q1A,H7VU!*=/TV,4#`(=!V$!`>G35P"-6NG><2NFD93!D3T&76.C3K5.[^ MH8U)=QR,I3$I_MCZ3O3V!-3VP#T!,ZI`#IMT[3!MTU;OTE-_]>G_`-,?1_5: MS_YZG_6?WQ4195%9-C(N)A%BN9,Z",F\31 M;O'Y/Z7NJ.W22)0,)C]H``B`;CJFBF_W2Z@^R"4R].)`F0,O$Y]XY5<*IUE- M(I:O;0<)$_O\(QAQ,J!`4'W`2`02`^YP2`P[F!,#;@0##U';;<=5=,OX6_\` M3_E%,N.@8J=_U?YQ2(;[?^';M`/0NP"`"4/0!`!$`_(!U2]M;+WZIA+7O2EZ M>WR\8K(KUI9+$UD&>)4>OSBLQNX`_,`VVZ>FWZ?PU]39JG$*<>>0GKH"3YO" M8$OVB/B0XIO4G!04)3,XIUUBG%13;;A^`AL.NBAK!01Y8Y5)2$_S`F/0V=.6 M:Z#MBL=N^9N$'K)TDH=%=L\9J%7:NFZQ!*=)RV53`Z1@'FN*OVWZ;]/ M4H2MD)(D1,&8(R^<5Z:I<8JVZD+6@I6DDI,C($9&)>'C9YB\4Y"%K^/2YDF7 M><\B1=++9VF1E'A9B]9%2@UV\HL$P>&CXF3LY/C?",<%CFXQ^X`C`Y MJXKY!M5;67W^DI;VM2N+]MULMZ4M3.@:`X7)!(!/D$B3D!$PGV]\Q\:7*EI- MM*N[B]UUC2`IEU+Q)7I`/YGM>V"2J7KQA[%/J0H[;;AZ;;"`;]-P'J`[:UH" M@L:AD?\`!C<-I*DMA*\Q/Z3P_9%>N8J0DGFCRAA^(V`;?F.1B5K"_CUF$'5( M!/W")3-JFS'1A6\@Y)M\*+!1(ZCA7_*DF(!N8Q0'W7&6P:GDK=U/M5A7MHJ5 M%:UG^!"!J5\Y)$IR$U1BKEGD>CXHV75;MKO.I@!#*?YW'#I21G.14<@?28@C MY-R#:PKUXQ,HV<$7()B"7NQ[O;>MYOBE6_9UN>NM1 M(I4HC2VGRG'7)4Y$C%(,C,9@RREL795AM]2QN'>-P1;*0B>@$%:DG`@)U(]0 M!SA3'*WF=QK=\=D^,W#NF9&I<*ZMC=_=KI96T?#O;E5(]-X1&MO5F[A2P*L% M7JB/8V6$A"M4>PP'*8=8YXSXDY&;W>-X/!L7B*E73LNK\[R@E+BF_*)&0!D0#,$YGK#11@#8IA$!.?N[ MPV$!#8P@3NZ[=PE_(`#]-;8*;<0`5R#9'EEV&&/C&G+SBC)D8M('E/>>*OCC M.*-=8HP:0@TA``;B`?F.VD)RQ'2*@+N;MZ@/X`4ASB/Z`!0$`]?4=@VT&,?4 MQ-]6DXQ<7;KMC%(X161,HDFN0JR2B)CHK%`Z*Q"J%*)T5B"!DSAN!R"`AIAT MCBJ:]EP)[@&+.D?-!I"#2$?2B`#N)NP`WW/U'M#;J([==@#5:G<2T\'%2D)Y MY9&7[8[H"5+`7Z8ZAA:_HXIRG0,WI9KAN_:==8UA!-4VO3\TJ[?'`Q[C9&ZF]F;SM MU];2L*I7VRK/(*3/IV!F.T?H*X>R95\RXQI64*9*I359NL$TFXJ20)[95T7` M&*H*C,R0!C*(7:IBJG4`R94CF**:R!B*)K$/W& M]WO*MVN$3BT9Q]5[+&FB"2<#*QIIU MN@ZA1D&#R.3F&CHY2-W\1671L.LD`I"'#G.4_P`N8G(YREUC(%+PAR;7(:?I;.XJG>\J3J1+ M5W_[H/\`C*-5L_%+D/2[%8ZQ9\2VN/FJE(P,986"*#:0"/=V=:.:P"?R6+I= M%R636EVQ4?;,(&,L'78!U=Z+D[85QH&[DWP8CAE"S)1274(8Q"!N8!$H`.KA3;ZV-5U+=(S=F2ZZ MXE"1,8J6)I'IS(Q`[8Q\%9QAOJC+K;]L>3[3*G5*EDE(FH^K(#P.,6'6",P( M'K!7&-+FV$E+/1XXT#)*3-M@H4I%Y&2@8=!NN]`\9X]!',9BH2C)B5-U55:M(UU](UVSEG9@Z$G( M6./_`-1((MX%^F@^:G8-CE+[**:A1,._>;<`U>;??[<])S]9[]'/SK3I\J3U M$DB?T,>;$KU+MQ0`=`02J:E8Y^?/`Y$"-@QKA[)&5%)6&I-"?S)8R+_N MR>LB[-]'L:G6X]B^=+OI28?+,H1G%R!4/H.J/>NJ0$TA$VX:^:[;[VO8M%9< MZQH-.+"$-I,U*)PQ$M6$YR&0!)PCO9MD[CO%.\Q2V]WWD347%`@)`$\,99`C M$'..?6&KV*I"T3M4#,5Q:3BFDU%I3D>YAEWT7(#LQEF:$@F15S&N3)&[3@7M M4(/<01#KKT-ONM%/GE!EB(D+%0**"\S$I!.P39]*1K5.>08QT-*.V<02 M1:*1#]S_`-1M"$^0Y20`P'*)EA],2;MYPV'MZL%IN[X]A:]*EHF2G$RG(X": M=,Y&,T[0^W3DO=%#_6-OTA]]("D)7(!1PGZO`SE]([9#>(3G1?7ZDM:*C"U$ MDBPL$G).7\E#&6;R<*14K:"&`@A]E5W85T>QD+N-*RRF?G)*1ECTR)Q& M`Z](E6<-<32&#N,N(,73#CW92IT]DREA2ADX%(LB<%',B1*-(7W$S&>**JG. MJ)EEE%#',.YM@CRY!W$QNW>5?N.G!#-4\%"9),@E*>N7I].2?2,`(E*XEVO6 M;*X\MFU[A+]92-+2J64U.N+_``4,>L*?UXZ,BQY%"B9,=RCVE,'=L'4-CB'< M'Z!M_/5%T$N(D@K"3ZM6DCY2)/UBEH(!T!(01B@B8/SR_9":;[PXXK9.DQF< MAC(3)(63E/N3(#H!A&.[OP[Q7N*H_6WG;]L=JYDE2V&UXG,CRX3Z]^L-C@DNV.S-QHQXBW,\;/S)-6LHT'Y34ATD!,HUD$EA2[5Q_H[@0W4>T>NKQ M_P"8N4AE?:R?QBTG[?N%,_[;M&K_`/,W_P"V-9D/%7P#E7[A\XXZUHKJ07%R MY^'/VU@B94.TYS)-6DZBW2(81`#%(0H#OL.OOI^<^6&V]*KY5ZI=XL]7]M'# M%P=-14VAE+O8)3+O+TQGS>-7AB$'5ZQ_LM"KU>HW"7O<'6W,W/+Q']T6`&99 M!])-G,FH::;G38)$1:/#+M$2E$I$@`PZ^`\QN*5--4[=M:;8965)`2F1GU,D@^'PCJSKB9A60E_O\E4RR MKU-BZ@D@G"1L^W;59RX1=J5*/0F(U\E$UDBS-/L;-!1]HI2@0X`&VK,UOW<] M/2FD8JEI;+GN8%0_,EZC)0F>\\XO3W$>R7JE-4NA;+R$:09)G*4A(Z<)3P[1 MMPX$Q^,)6JLQC'<-5:FX6=1=9AG)(F`4=JOT)9.0>L46YRNGC67(+Q(X"F_6-M1QC5$4I$RD8#Z3E#QRS^=DE$I&==NXCVQAWZ\@]17!9_#G03, MU5,7N1,0HE$.T-4S=:];:6G'?RD`A*4ITI`)F1*?4DDQ]K>V[0H*Q!%IBIQDA"14H`H$?GAY1@6.>QTBY*@51VR61*`BD M`D(!@`0+T#5>CO=PHFG6$/*4RZL*(,R-0,P<3F#UE'QU>U;'7OL5;],VEZF3 MI0`!(ID4R,AA,'*-23XTXB*XG7PU!H,I/1:D$M*F5*>5C8`R:*2=>@9(R`NX M>$;(MR)(H)&`J2?0-?4]NR_K931"H<_1I5JD%$#4@+(=ZX3/[_P!]K!C* MPTLJTX\E0N:X]XAM5.6Q]8J##2].,_92#FO/! M67CWB\:_5DHQF]`7":CZ+CGJ@J)LE^]JF)M@3VU;_P"Y]R(K3=&*A:+AB"HF M9*2)&1P"21@8N"]B;579Q9G*1I5*%!0`2!(@@C'&JW%./+)))ZDYD]X]Y0T-);&TL6Y"6:=(D$@98>$HS7 M:'3<`'8?I`?P_A^6VVOG0'$B04`/A'T@J;"BDE1/RBH-]NOKKO\`'&.C84$^ M;U?6/ND=XA6\KO))S[PM^X7P+XR*7RGN7_UER38\!1=B),T;"LGD(&N2:R63 ML_P;D.,$3MUCN@W;F^.;XY>A0_$4(EN9KJEN>8)N$+3,LW/'MTA:7)O(/*,2 MRI\K:&LO7X=P[:2,N5O)++G* M7A=XS7O+&Z$OMYX8QG.?F!R"85[&M4RC9&-B8PK:IX(P#,S.\T%" MUY3P^SN*T@M&6:GW=FC$&L%)S"+MS&NW#59NOVJ'(5"%$^2+GCB[ MQN\0\I%7D15,38&@K7\UYC M6MP^/7T1+,,C)1,%\1667LRLFM(JJ'*4R`"4P(1I7A-\LLQS]C,^<=N0#&N5 MOFMPUOM@QQFJ/J[-6(K.0XR!L\O4$,K5.#7'3,EV MHKIE!"'XM(0:0@TA!I"$Z*7(C+7+C M)YLGW6L[;?J4-OJWV$P`.P%*81,&_0.@"/J(>H(1P.4Y3\ M4[QLFR1,9,H_$'"6/"*"!>Q(G$GC\(%Z;E,?&-:44`!#\/<,.D(@#^/>Z9*QY^X@\I,EBF\ MS^/7["N^22TNI*#8UN5064H,K.7V$0F(RTPD[$/XP;7"-!.`))K;FV(J0#&[ MD(>?\-W/OR6^4OQ^\V\L91Y6/<86S!]CM[BJY,QKC'%3*SOI.,P\TN,-2F\- M(5%_5HBFPS]E\I\N5F>6D3R())N4$D1`Z$:QP3_DN8/'-ABXS.& M,!<2<0V>T9INU.3KILHY1S)%3-,K4A28>PSL;/L:E2:%-VM5JX.R:_/DGL>J M85TFXE(9".%T'RK7FV9W\P?B0Y(S[:[Y!P!@;DK8N/6931D3!6#)F,F&(GDN M[J608JO-&5>7OE2A;(@L$@R;LDY%N@N=1N15/"KR0P/BR\%?-SDZ[@ MT+==U.8\;CS#]*=N#-HVTY0M.'ZPK"-YU=$Q'B5;A&$:ZDWXH""JB#,42F*9 M4HZ0A]GE3S@YL<(/$_Q9\JC[.LCF?(]M5X]7K/\`AJSUNF1&%;E1,]L49&0I MN/HJ%KL?9,;R-0++LTHV12?O%SBBPQLO&58L#/5@Y)QX@T7=JK) MF;(G2(!C"A#2/`_BK5O)3Y*?(?9\@Y'R]4NM3*>\KU`HKR0A,ENZM!QU*;LTK?1;7!H&!XX1 MJ='K,.PK,558$]13*BQ(=5BY.H_[G!RG*W1:T5%J66L1* MB\K18"`/LL+Q7O7"_A M]2([D4ZAI93#5"Y(X[C;O6FU>O%Y*W^P4DF4*BF0J#I\JV0^8S;%4,7Y!3:0 MCD_G^X]XH\@,AP(XWXE85+(O+&P\JZ#;(VT4S[;.6+%W&>O,Y"2S+>+E9H;Y M1H#'R;,61FH/U$T)"6%`C8IE0$00A7G[@+QIS'DYX`6;&.-$&BV=\33K3,.# MTG78W2L%E@HI]'3E%,Z5,1)I_>E7E%V[)3EGB>.\6 MW'AUEZZ0.)[9QFPS&8FY$U'(4@C4;1B2YX6C%*O9HFW5Z>5:33)44X('#0WL MF^>W634;^X4X:0A@GQ0<"K15*YY;O,+R6AS8L4Y8>&:R7PY-RU=#'N)G9FFOV>THZ$$BF$_TZ0A MD_A!POR=S2\!G-'&V'(M:R9QP=SAI7)>%Q&R4`EZO5$A<),Z7<5*]6C`$K-G MC8Z=5=-R))""ZS0Z)!,L8A#(1/S\8_,G`+;Q:<,;*\R!"J3%3X[XKQU.8ZC7 MC20R<3)U&JS*HSF.4<>M'*EH-/[ M]PGRJM7*6'1QS5N:V$,GY0PK=)-P9I19R,LIR3YE&U+ M,>7;=@(N+GD!09EXX096J-A"HOR*.FAUFZD@9N@D8ZIC`5"&:.%_"3)G-C]O MSRPH6&HIQ9L[8#YTP?(^)Q$Q4#^]KK0&&%HFE7$\!6#?_*2SADSECNFWM)&] M]1BH@F(JG`@H1(:\F]LA^2G[;7@[QOP:L&2>0&88OA1B.BX8JHDDLCO<@4*& MAVMYKSZI)*#-0IZ6XKKHLJJ]202CP(!G!DRFWTA"4L@\H>)/AWS'POXR\SX3 MD74>0WCSXFXT8X/SKQCIN.I=[=97.U:M%FS[`7&7R0^)'V[&$#;;&ZBHF**T M.W3<%6=^\1?<`0AYWP&\%F&8X;D-?K%+X_P!R5^0DX![%5V;LADTXMH5DG'E>`*;<2J'4%"&\^<'C5R)4?W+/ M%3)6$_N]7PWY"JW;)+D$,"W,C%R$)BVOM'/(RF39NT&GV_)58BX8[@@@!U5Y M%8X")MQ!")N/MAW=O:G[.P%[.P.I1*)1)VAL0I2D`I0Z#N&^D(\4C$1DQ'/( MB88,Y:*D6RK.0C9-HV?Q[]HN7M6;/6+I)5H[05+T,10ABFW'<.HZ0C0:%A/# M6*G$H[Q?B7&6-GT>BF?@F5\:FU*OU@7Q4=_8(]^R1S'YB2`"($(KWE+^`;@`@A& M^=A=BAMT*&P%W$`'_P`P!MW]1WZ^@]=(1SJ>P[B2TSR5IL^+L=62SHBU%*QS M]'K$Q/IF9;_%,28D8MS(E%N`[$V4^C_+MI"-V?Q$;*-3,9-BTD6)]O<9/VS= MZT5$IP.056KI-9`X)'*`D`2]I!#H`;!I",46E4XA7)4ZE6$P>I%0=@2OQ!0< MHD6(X32<`#/9=)-PF50I3@8H'*!MMP`=(1Z8^KUR)7!W%0,+&.P1^/\`+CHF M.8N1;>X"OQA6:-43_'%8`/V;[=P;Z0C"1V,L<1%A>6^*H%)C+;(JK+2%ICJG M7V%D?KN=A<+O)UI'(R;A=<2@)SG5$QA#KI",G8Z;4[E'A$7"M5^V1!5B."15 MFA(J?C2+I@(%7!E*M';<%@[AV/V]P;B`#I"+B=2K"40VKR5>@TZ\R00;,Z^G M$1I()JW;'%1N@WB"-2L$44#[&(4J8`00W+L.^Z$7&-8KD6N9U&0,+&NSI>R9 MW'Q,E*.4G"H=QRG5$##ZZ0AFV:Q/QXRYS6Y:Q/DDQ M?AN[G8RF.'W#*8S]5JH[Q\''!?'L,2R1..+#;$D8L+%N,F`.6V=/(QP!XH5XV/^&O!+.==LP8&KH5>HO$SS4OOEG5QYS7O>#9 M+!49A/&^0L5M*E*!,.XYYF^_75E_>0EX&%Q;38AN*YD2E(^FW+< +3&,VWTA#^FD(_]D_ ` end -----END PRIVACY-ENHANCED MESSAGE-----